Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1...
Journal Information
Vol. 36. Issue 4.
Pages 324-325 (May 2021)
Vol. 36. Issue 4.
Pages 324-325 (May 2021)
Letter to the Editor
Open Access
Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert's disease: Sleepiness and role of Epworth Sleepiness Scale
Guía clínica para el diagnóstico y seguimiento de la distrofia miotónica tipo 1, DM1 o enfermedad de Steinert: somnolencia y papel de la escala de somnolencia de Epworth
Visits
...
A. Romigi
IRCCS Neuromed Istituto Neurologico Mediterraneo, Sleep Medicine Center, Pozzilli (IS), Italy
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor:

I read with great interest the study by Gutiérrez Gutiérrez et al.1 “Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert's disease.” The authors propose these clinical guidelines as a reference for healthcare professionals involved in the diagnosis and follow-up of MD1. Although this topic is difficult to analyse in depth, the authors underscore the presence of sleep disorders and somnolence, together with fatigue, in MD1. They assert that fatigue is associated not with muscle weakness but with sleep disorders and somnolence. Furthermore, these guidelines consider the Epworth Sleepiness Scale (ESS) “a good instrument for diagnosing” sleep disorders, citing the validation study by Johns.2 In their Table 1, they also recommend the use of the ESS to diagnose somnolence and fatigue. These statements are only partially correct.1 On the one hand, the third edition of the International Classification of Sleep Disorders3 defines daytime sleepiness as “the inability to stay alert and awake during the major waking episodes of the day, resulting in unintended lapses into sleep.” On the other hand, fatigue is defined as “reversible motor and cognitive impairment, with reduced motivation and desire to rest.”4 Although these 2 concepts are very different, the terms may be used interchangeably in everyday speech, as well as by patients and physicians. Fatigue and excessive daytime sleepiness (EDS) manifest in 62.5% and 30%-39% of the patients with MD1, respectively.5 Despite the high prevalence of sleep apnoea syndrome (SAS),5–8 several authors have been unable to show a correlation between EDS and SAS. From a methodological perspective, EDS in neurological diseases has been analysed using different measurement tools. The most frequent subjective scale is the ESS, a reliable questionnaire used in several surveys. Several factors have contributed to the extensive use of the ESS in assessing somnolence: the questionnaire is self-administered and easy to complete and score, making it suitable for quickly assessing EDS in outpatient clinics. It is currently thought to be the most widely used scale for assessing/screening for somnolence and has been translated and validated in several languages and countries. However, the ESS is not applicable to all clinical contexts. Somnolence and fatigue are strongly associated with MD1, and the ESS requires the performance of some activities that patients with MD1 do not frequently perform. Therefore, different tools have been proposed to assess somnolence and fatigue in MD1. Laberge et al.9 validated the Daytime Sleepiness Scale (DSS), a self-administered scale more in line with the clinical characteristics observed in MD1 patients with somnolence (ie, naps, narcolepsy-like phenotype, and somnolence related to attention). Furthermore, the fatigue severity scale (FSS) has been considered the most important tool for assessing fatigue in MD1.10 Very recently, Laberge et al.11 assessed EDS and fatigue in a large, 9-year prospective study of MD1 using the DSS and FSS, and reported that high body mass index was a potential risk factor for both symptoms. In an exhaustive evaluation of both somnolence and fatigue in MD1, Hermans et al.12 developed the Fatigue and Daytime Sleepiness Scale (FDSS) with the Rasch model, using the 22 items of the ESS, DSS, and FSS to obtain a scale of 12 items after rescoring and removing misfitting items. This scale showed good reliability and internal consistency and was able to distinguish between patients with MD1 and fatigue and those with EDS.13 Therefore, we should underscore that the ESS does not represent a “good instrument for diagnosing” sleep disorders and is not the best subjective scale for assessing somnolence, with the DSS and FDSS being more appropriate tools for assessing the clinical status of patients with MD1, and more useful for distinguishing fatigue from EDS in this context.14

Acknowledgements

I would like to thank Dr. Daniela Rossi for her invaluable help in reviewing the manuscript.

References
[1]
G. Gutiérrez Gutiérrez, J. Díaz-Manera, M. Almendrote, S. Azriel, J. Eulalio Bárcena, P. Cabezudo García, et al.
Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1 MD1 or Steinert's disease.
Neurologia, 35 (2020), pp. 185-206
[2]
M.W. Johns.
A new method for measuring daytime sleepiness: the Epworth sleepiness scale.
Sleep, 14 (1991), pp. 540-545
[3]
American Academy of Sleep Medicine.
The International Classification of SleepDisorders – Third Edition (ICSD-3), 3rd ed.,
[4]
R.J. Mills, C.A. Young.
A medical definition of fatigue in multiple sclerosis.
QJM, 101 (2008), pp. 49-60
[5]
M. Maestri, A. Romigi, A. Schirru, M. Fabbrini, S. Gori, U. Bonuccelli, et al.
Excessive daytime sleepiness and fatigue in neurological disorders.
Sleep Breath, (2019),
[6]
A. Romigi, V. Franco, F. Placidi, C. Liguori, E. Rastelli, G. Vitrani, et al.
Comparative sleep disturbances in myotonic dystrophy types 1 and 2.
Curr Neurol Neurosci Rep, 18 (2018), pp. 102
[7]
A. Romigi, M. Albanese, C. Liguori, F. Placidi, M.G. Marciani, R. Massa.
Sleep-wake cycle and daytime sleepiness in the myotonic dystrophies.
J Neurodegener Dis, 2013 (2013), pp. 692026
[8]
A. Romigi, F. Izzi, V. Pisani, F. Placidi, L.R. Pisani, M.G. Marciani, et al.
Sleep disorders in adult-onset myotonic dystrophy type 1: a controlled polysomnographic study.
Eur J Neurol, 18 (2011), pp. 1139-1145
[9]
L. Laberge, P. Bégin, J. Montplaisir, J. Mathieu.
Sleep complaints in patients with myotonic dystrophy.
J Sleep Res, 13 (2004), pp. 95-100
[10]
L. Laberge, C. Gagnon, S. Jean, J. Mathieu.
Fatigue and daytime sleepiness rating scales in myotonic dystrophy: a study of reliability.
J Neurol Neurosurg Psychiatry, 76 (2005), pp. 1403-1405
[11]
L. Laberge, B. Gallais, J. Auclair, Y. Dauvilliers, J. Mathieu, C. Gagnon.
Predicting daytime sleepiness and fatigue: a 9-year prospective study in myotonic dystrophy type 1.
J Neurol, 267 (2020), pp. 461-468
[12]
M.C.E. Hermans, I.S.J. Merkies, L. Laberge, E.W. Blom, A. Tennant, C.G. Faber.
Fatigue and daytime sleepiness scale in myotonic dystrophy type 1.
Muscle Nerve, 47 (2013), pp. 89-95
[13]
B. Gallais, C. Gagnon, G. Forgues, I. Côté, L. Laberge.
Further evidence for the reliability and validity of the Fatigue and Daytime Sleepiness Scale.
J Neurol Sci, 375 (2017), pp. 23-26
[14]
C. Gagnon, C. Heatwole, L.J. Hébert, J.-Y. Hogrel, L. Laberge, M. Leone, et al.
Report of the third outcome measures in myotonic dystrophy type 1 (OMMYD-3) international workshop Paris, France June 8, 2015.
J Neuromuscul Dis, 5 (2018), pp. 523-537

Please cite this article as: Romigi A. Guía clínica para el diagnóstico y seguimiento de la distrofia miotónica tipo 1, DM1 o enfermedad de Steinert: somnolencia y papel de la escala de somnolencia de Epworth. Neurología. 2021;36:324–325.

Copyright © 2020. Sociedad Española de Neurología
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos